Viveve has an experienced and highly regarded Management Team, Board of Directors, and Advisory Board. Together, they provide the leadership, resources, and direction necessary to achieve commercial success.

Scott Durbin

Scott joined Viveve in early 2013 and became Chief Executive Officer and Director in May 2018. He previously served as the company’s Chief Financial Officer and has been instrumental in the company’s growth. He is committed to leading the company and the clinical and commercial development of its innovative CMRF technology to solidify its position as a global leader in women’s intimate health. Scott’s 25 year career in the life sciences industry covers corporate finance, strategy, clinical, and operational experience. Prior to joining Viveve, he was Chief Financial Officer of Aastrom Biosciences, a publicly traded, cardiovascular cell therapy company. Before Aastrom, he spent six years as Chief Operating and Financial Officer for Prescient Medical,Inc. (PMI), a privately held company that developed diagnostic imaging catheters and coronary stents designed to reduce deaths from heart attacks. Prior to PMI, he spent several years as a financial consultant for two publicly traded biotech companies, Scios, Inc. – a Johnson & Johnson company and Alteon, Inc. He began his career in corporate finance as an investment banker in the healthcare and M&A groups at Lehman Brothers Inc., where he focused on mergers and acquisitions and financings for the life science industry. At Lehman, he successfully executed over $5 billion in transactions for medical device and biotech companies. He began his career as a Director of Neurophysiology for Biotronic, Inc.

Scott received a B.S. from the University of Michigan and an M.P.H. in Health Management with Honors from the Yale University School of Medicine and School of Management.

James Atkinson

James Atkinson has over 30 years of experience in medical device sales, marketing and business development with both Fortune 50 and start-up device companies. He joined Viveve as Chief Business Officer and President in February, 2015. Prior to joining Viveve, Mr. Atkinson was a principal at Ulthera, Inc. from October, 2006 through April, 2014, where he served as Senior Vice President of Sales and Marketing and Senior Vice President of Global Sales. While at Ulthera, he helped grow the company from 3 to 165 employees and established a global distribution network that included 42 distributors, covering 52 countries. Ulthera was purchased by Merz Aesthetics for $600 million.

Before joining Ulthera, Mr. Atkinson served as Vice President of Sales and Marketing for the Cardiac Surgery Division at St. Jude Medical, Inc. where his responsibilities included launching the Biocor® stented tissue valve, recognized as the fastest growing heart valve brand in the industry. Prior to St. Jude Medical, he served as Vice President of Sales for Medtronic Vascular, a $200 million division of Medtronic, Inc. Mr. Atkinson’s entrepreneurial spirit led him to co-found and serve as Vice President of Sales and Business Development for Medical Simulation Corporation, the leading developer of state-of-the-art simulation technologies and services for the cardiology, cardiac surgery and nursing industries. His career began as a sales representative at Ethicon Endosurgery, a Johnson and Johnson company, where he progressed through positions of increasing responsibility to Regional Manager.

Suzon Lommel

Suzon Lommel has more than 30 years of experience in the medical device industry developing regulatory and quality systems. She currently serves as the Senior Vice President of Regulatory and Quality Affairs at Viveve. Prior to joining Viveve, she was Global Vice President of Regulatory and Quality Affairs at Ulthera, Inc. which was acquired by Merz Aesthetics in July, 2014. Additional prior experience includes executive and senior management roles at Breathe Technologies, Inc., Foxhollow Technologies, Inc., Advanced Stent Technology, and Boston Scientific. Suzon has extensive experience with the U.S. Food and Drug Administration and international regulatory agencies. She has authored numerous 510k, IDE, PMA, and international submissions. Ms. Lommel holds a degree in Physics from Moorpark College.

Jim Maffezzoli

Jim Maffezzoli joined Viveve in March 2018 as Senior Vice President of Global Marketing. Most recently Jim served as the Vice President of Marketing at Allergan (AGN) where he was responsible for building the Women’s Health therapeutic portfolio in the U.S. to a $1.1B enterprise achieving +17% growth. He spearheaded the successful launches of numerous new products and partnered with business development in evaluating multiple licensing and acquisition opportunities.

Prior to Allergan, Jim served as the Global Head of Marketing at Exeltis USA, Inc., a Division of the Grupo Insud, where he built the Women’s Health and Dermatology businesses through internal product development, licensing and acquisitions, geographic expansion, and improved in-country sales effectiveness. He contributed to 40% growth over a three-year period at Exeltis and established a global marketing group, integrated a digital marketing strategy, and a Customer Relationship Management platform. Jim’s senior management career includes ten years with Pfizer Inc. (PFE) where he served on marketing leadership teams for urology and women’s health, and as Early Commercial Lead to build the global product pipeline. He was responsible for the consumer strategy and advertising group where he drove enhancements across a multitude of brands. He has recorded success in consumer marketing from his position as Director of New Products, Consumer Medicines Division for Bristol-Myers Squibb (BMY), and his nine-year tenure with Kraft/Nabisco (now Mondelez International, Inc. [MDLZ]) where he led brand teams in three different business units.

Over the last 20 years he has successfully driven growth and created value in diverse businesses through the application of strategic planning, innovative brand building, product pipeline development / lifecycle management, business development, and cross functional leadership in multiple industries and therapeutic areas.

Jim holds a M.B.A. from the J.L Kellogg Graduate School of Management at Northwestern University, and a B.A. in Political Economy from Princeton University. He also serves as Chairman of the Board of Trustees for the Metropolitan Montessori School in New York City.

Debbie Wilkerson, Ph.D.

Debbie joined Viveve in 2015 and was promoted to Vice President of Clinical Affairs in August, 2016. She assumed additional responsibility for Medical Affairs in November, 2016.  Debbie brings over 17 years of experience in life sciences including pharmaceutical, biologics, medical devices and women’s reproductive health. She has extensive clinical affairs leadership experience across multiple therapeutic areas as well as experience in operations and regulatory affairs. Debbie has launched many U.S. and international trials in women’s health, immunology, urology, orthopedics and dermatology. In connection with this work she has published numerous articles in peer-reviewed publications.

Prior to joining Viveve, Debbie served as the Director of Clinical Research for Medtronic Spine and Biologics (MDT), Medtronic’s second largest business, and managed a high profile biologic. She was Executive Director of Clinical Operations at OV Clinical Trials in Colorado and Director of Research and Development at Alita Pharmaceuticals. As an Associate Director and then Director of Clinical Operations at Duramed Research, Inc., a subsidiary of Barr Pharmaceuticals, Debbie focused on women’s health programs, including bringing Plan B emergency contraception OTC. Previous to these executive management roles, she was Director of Scientific Affairs at Women’s Capital Corporation responsible for operations, safety, FDA submissions, marketing and external collaboration, which was preceded by her role as Research Associate at The David and Lucile Packard Foundation.

Debbie received her Bachelor of Science in Chemistry degree from the University of Michigan and earned her Doctorate in Biochemistry from the Stanford University School of Medicine.

Jim Robbins

Jim joined Viveve as Vice President of Finance in July 2014 and was promoted to Vice President of Finance and Administration in May 2017. In May 2018, Jim assumed expanded responsibilities and was appointed as the Company’s Principal Accounting Officer. He has over twenty years of accounting and finance experience in both industry and public accounting. Prior to joining Viveve, Jim provided accounting, finance and business consulting services for various biotech companies. From 2010 to 2012 he served as Vice President of Finance and Administration for Auxogyn, Inc., a privately held medical technology company focused on advancing women’s reproductive health by translating scientific discoveries in early embryo development into clinical solutions that improve patient outcomes in vitro fertilization (IVF) procedures. He served as Director of Finance and Vice President of Finance 2004 to 2010 for Micrus Endovascular, Inc., a company which develops, manufactures and markets both implantable and disposable medical devices used in the treatment of cerebral vascular diseases. Prior to Micrus Endovascular, Jim served at Genitope Corporation as Corporate Controller, a biotechnology company focused on the research and development of novel immunotherapies for the treatment of cancer. From 1995 to 2001, he served in management positions for high technology companies including Extricity, Inc., InVision Technologies, Inc., and Truevision, Inc. Jim was in the audit practice of Price Waterhouse, LLP from 1987 to 1995.

He received his Bachelor of Business Administration with a concentration in accounting from the University of Texas at Austin and is a Certified Public Accountant.

Marty Kerber

Marty joined Viveve, Inc. in January of 2018 as the new Vice President of Operations, bringing a wealth of experience from the medical device field. As a General Manager, Chief Operating Officer and Senior Vice President at multiple device companies, his comprehensive expertise spans engineering, manufacturing operations, managing contract manufacturers, product development, plant engineering, process development, new product launches, Lean/Six Sigma processes, supply chain and customer service.

As COO, Chief Engineer and later the Vice President Corporate Engineering at inSleep Health, Marty created the manufacturing organization and drove the commercialization of the innovative sleep disorder breathing product. In his capacity as the General Manager of MME Group, Inc., he took the organization from tool making to a contract manufacturing company that created highly regulated customer products for Fortune 500 medical companies. As Vice President of Engineering at Covidien, Ltd. he realigned the organization in preparation for separation from Tyco (TYC) and created the Advanced Manufacturing Engineering function in support of an increase of $50 million in NPI spending. He holds seven patents and three certifications.

Marty received his B.S. degree in Engineering Mechanics from the U.S. Air Force Academy, an M.S. degree in Materials Engineering from the University of Alabama, and a MBA in Production and Operations Management from the University of Colorado.

He grew up on a small family farm with 10 siblings and considers himself a small-town boy at heart who chased his dreams to make the world a better place.

Sean Shapiro

Sean joined Viveve as Vice President of U.S. Sales in September, 2016 and brings extensive experience in medical device and aesthetic industry sales, commercial team organization, development, and management. Most recently, Sean served as Director of Sales, Merz North America, Aesthetic Device Division where he was responsible for capital and consumable sales of $100M annually directing a team of 50 regional and direct sales professionals. He led the commercial launch of the Cellfina™ System that in 12 months became the market leader generating over $15M in sales. A Regional Sales Director at Ulthera, Inc., Sean managed a team selling new ultrasound tissue lifting technology and capital equipment to physicians in the aesthetic marketplace earning top sales awards personally and with the team he led. At Zeltiq, Inc. he served as an Area Sales Manager and launched CoolSculpting®, again earning sales revenue and management awards. Prior to this, Sean had five years as a successful Area Sales Manager at Lumenis, Inc.

A known and respected sales leader in the aesthetic marketplace, Sean has consistently received annual awards and recognition for top sales dollar volume, region and territory revenue, new technology and product launches in addition to sales management and business development accomplishments.

Sean earned his Bachelor of Science in Communications from the University of Arizona.

Lori McMillan

Lori has over 20 years of leadership experience in human resources and strategic talent management in healthcare and technology industries. Prior to joining Viveve in May 2017, she was Vice President of Talent Management and Chief Administrative Officer at The Breakaway Group, a Colorado-based business that develops simulation education of HIT applications for over 1 million healthcare provider end users. Lori has held senior leadership positions demonstrating success in creating and implementing effective human capital and operational strategies in support of organizations’ mission, values and goals. She served as a human resources executive at the Association of periOperative Registered Nurses (AORN) and Evolving Systems, Inc., a software company which tripled in size prior to their IPO. Early in her career, Lori held management and sales executive positions in the cosmetics and fragrance industries with Estee Lauder and Riviera Concepts. She received her Bachelor of Arts degree in Sociology at Colorado State University and completed HR executive and business education programs at Stanford University and Vassar College.

Lori H. Bush

Lori Bush joined the Viveve Board in May, 2016 with over 30 years of experience in the consumer and healthcare product industries. Ms. Bush served as President and CEO of Rodan + Fields from October, 2007 to May, 2016. During her tenure, the company re-launched under a transformative social commerce model and grew to become one of the largest premium skincare brands in the U.S. Prior to joining Rodan + Fields, she served as President of Nu Skin, the global personal care division of Nu Skin Enterprises and worked at Johnson & Johnson Consumer Products Companies as the Worldwide Executive Director over Skin Care Ventures. Lori also served as the Vice President of Professional Marketing for Neutrogena.

Lori is a frequent speaker at industry and academic events, has authored numerous papers on health, beauty, and women’s leadership and is co-author of a best-selling beauty and wellness book. Her passion and career driver has been developing integrated approaches to consumer health and beauty to help women live more satisfying lives. She earned her B.S. from The Ohio State University and M.B.A. from Temple University.

Scott Durbin

Scott joined Viveve in early 2013 and became Chief Executive Officer and Director in May 2018. He previously served as the company’s Chief Financial Officer and has been instrumental in the company’s growth. He is committed to leading the company and the clinical and commercial development of its innovative CMRF technology to solidify its position as a global leader in women’s intimate health. Scott’s 25 year career in the life sciences industry covers corporate finance, strategy, clinical, and operational experience. Prior to joining Viveve, he was Chief Financial Officer of Aastrom Biosciences, a publicly traded, cardiovascular cell therapy company. Before Aastrom, he spent six years as Chief Operating and Financial Officer for Prescient Medical,Inc. (PMI), a privately held company that developed diagnostic imaging catheters and coronary stents designed to reduce deaths from heart attacks. Prior to PMI, he spent several years as a financial consultant for two publicly traded biotech companies, Scios, Inc. – a Johnson & Johnson company and Alteon, Inc. He began his career in corporate finance as an investment banker in the healthcare and M&A groups at Lehman Brothers Inc., where he focused on mergers and acquisitions and financings for the life science industry. At Lehman, he successfully executed over $5 billion in transactions for medical device and biotech companies. He began his career as a Director of Neurophysiology for Biotronic, Inc.

Scott received a B.S. from the University of Michigan and an M.P.H. in Health Management with Honors from the Yale University School of Medicine and School of Management.

Dan Janney

Dan Janney is the Managing Partner of Alta Partners. Dan joined Alta at its founding and has over 20 years of successful early stage investing experience in life sciences. His focus on working with exceptional entrepreneurs to create companies around novel insights in biology and new approaches to drug discovery has led to the funding and development of over 35 companies. Prior to Alta, Dan was a senior investment banker at Montgomery Securities where he advised life science companies on over $8 billion of equity and merger transactions.

Dan is currently on the board of directors of several public and private companies, including Esperion Therapeutics (NASDAQ:ESPR), Evolve Biosystems, Prolacta Bioscience, Sutro Biopharma, and Viveve (NASDAQ:VIVE). In addition, he led Alta’s investments in Astex Pharmaceuticals (acquired by Supergen), Cellective (acquired by Medimmune), ChemGenex (ASX:CXS acquired by Cephalon), CoTherix (NASDAQ: CTRX acquired by Actellion), Definity Health (acquired by United Health), Dynavax (NASDAQ:DVAX), Endonetics (acquired by Medtronic), Ilex Oncology (NASDAQ:ILXO acquired by Millennium Pharmaceuticals), InterMune (NASDAQ:ITMN acquired by Roche), LJL Biosystems (NASDAQ:LJLB acquired by Molecular Devices), Mako Surgical (NASDAQ:MAKO acquired by Stryker), Neothetics (NASDAQ:NEOT), and Triangle Pharmaceuticals (NASDAQ:VIRS acquired by Gilead).

In 2006 and 2007, Dan was listed in Forbes’ Midas 100 List of Top Tech Investors. He is a member of The President’s Council of the J. David Gladstone Institutes and serves on the Board of Regents of Georgetown University. He holds a Bachelor of Arts in History from Georgetown University and a Master of Business Administration from the Anderson School at the University of California, Los Angeles.

Debora Jorn

Ms. Jorn has served as a member of the Viveve board of directors since May 2016. She has 30 plus years of commercial experience building global pharmaceutical, aesthetics and OTC businesses. Debora is a recognized leader in creating new markets and has successfully launched products in numerous therapeutic areas. She has an extensive background in several areas of Women’s Healthcare including overactive bladder and incontinence, fertility, contraception, osteoporosis, and aesthetics. Most recently, Deb was Executive Vice President of Corporate and Commercial Development at Eyepoint Pharmaceuticals. Prior to that, Ms. Jorn was Executive Vice President and Group Company Chair at Valeant following the acquisition of Bausch & Lomb where she was the Chief Global Marketing Officer leading the prescription and OTC eye health business. Before joining Bausch & Lomb, Debora was the Group Vice President of Women’s Healthcare and Fertility at Schering Plough Corporation. Ms. Jorn began her career at Merck & Co., Inc and for more than 20 years held roles of increasing responsibility in R&D, Marketing and Sales. Ms. Jorn has a strong scientific background and extensive experience in all facets of the clinical development process leading to product launch including market and competitive assessments, clinical strategy, and trial design, labeling requirements for approval and competitive differentiation. PharmaVoice has recognized Ms. Jorn as “one of the top 100 most inspiring people in healthcare” in the “brand builders” category.

Arlene M. Morris

Arlene M. Morris joined the Viveve Board in May, 2016. Ms. Morris was previously the chief executive officer and president of Syndax Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of an epigenetic therapy for treatment-resistant cancers from April, 2012 to May, 2015 and a member of the board of directors from May, 2011 to June, 2015. Prior to Syndax, Arlene served as the president, chief executive officer and a member of the board of directors of Affymax, Inc. from 2003 to 2011, a publicly traded biotechnology company. She has held various management and executive positions at Clearview Projects, Inc., a corporate advisory firm, Coulter Pharmaceutical, Inc., a publicly traded pharmaceutical company, Scios Inc., a publicly traded biopharmaceutical company, and Johnson & Johnson, a publicly traded healthcare company. Arlene is currently a member of the board of directors of Neovacs, SA, a French publicly traded biotechnology company, Dimension Therapeutics, Biodel, Inc., and Palatin Technologies, Inc., all U.S. biopharmaceutical companies. She is also on the board of the Foundation for Research Development of the Medical University of South Carolina and previously served on the Board of BIO and the Humane Society of Silicon Valley. Ms. Morris received a B.A. in Biology from Carlow College.

Jon Plexico

Jon Plexico joins the Viveve Board of Directors with approximately 24 years of life science industry operational and advisory experience, including eight years as Managing Member and Founder of Stonepine Capital Management, LLC. Previously, Mr. Plexico was Managing Director at Merriman Curhan Ford & Co., now known as Merriman Capital, where he ran healthcare corporate finance focusing on private investments in public equity (PIPEs), secondary offerings, and mergers and acquisitions. Prior to that, Mr. Plexico was co-founding partner of Venture Ready Partners, a life science advisor providing capital raising services to private biotechnology companies. Mr. Plexico was employee #5 and served as director of business development at Chemdex Corporation, an electronic life-science commerce company that grew to 500 employees and completed an initial public offering during his tenure. He began his career at Quidel Corporation, where he became National Sales Manager for the Autoimmune Division. He has served on the Boards of Directors of Zila, Inc. and Immunetech, Inc. Mr. Plexico is a graduate of Colgate University.

Patricia Scheller

Patricia continues to serve on the Viveve Board having resigned as Viveve’s Chief Executive Officer in May 2018. She assumed the role of CEO for Viveve in May 2012. Patricia’s commitment to the healthcare industry spans more than 25 years. Prior to joining Viveve, she served as the CEO of Prescient Medical, Inc. (PMI), a privately held company that developed diagnostic imaging catheters and coronary stents designed to reduce deaths from heart attacks. Before PMI she was the CEO of SomaLogic, a molecular diagnostic company dedicated to developing protein signature arrays. Patricia also managed several business units at Ortho-Clinical Diagnostics, a Johnson & Johnson company, and served in key executive positions at Dade Behring, a clinical diagnostics firm. In addition, she was director of cardiology systems at Cordis, a Johnson & Johnson company renowned for pioneering vascular disease treatments. There, she was responsible for launching the PALMAZ-SCHATZ® balloon-expandable stent, the first stent to achieve over a billion dollars in sales.

Patricia received a B.S.E. degree in Biomedical Engineering from Duke University and completed executive business education programs at Harvard University, Massachusetts Institute of Technology, Columbia University and Northwestern University.

Sheryl A. Kingsberg, Ph.D.

Dr. Sheryl Kingsberg is the chief of behavioral medicine at MacDonald Women’s Hospital/University Hospitals Case Medical Center and Professor in Reproductive Biology and Psychiatry at Case Western Reserve University. Her areas of clinical specialization include sexual medicine, female sexual disorders, menopause, pregnancy and postpartum mood disorders, and psychological aspects of infertility.

Dr. Kingsberg’s primary research interests are in treatments for female sexual disorders and the psychological aspects of infertility and menopause. She has been the principal investigator for several clinical trials for treatments for female sexual disorders and consults for many pharmaceutical companies that are developing investigational drug treatments for sexual problems. She has numerous publications in many national and international journals and is an Associate Editor for the Journal of Sexual Medicine and sits on the editorial board of the journal Menopause.

Dr. Kingsberg is a leader in a number of national and international organizations. She currently sits on the Board of Trustees of The North American Menopause Society, and is a past president of The International Society for the Study of Women’s Sexual Health.

Michael Krychman, M.D.

Dr. Krychman is Executive Director, President, and CEO of the Southern California Center for Sexual Health and Survivorship Medicine and Associate Clinical Professor at the University of California, Irvine, Department of Obstetrics and Gynecology. He is a Member of the International Society for the Study of Women’s Sexual Health (ISSWSH), The International Society for Sexual Medicine (ISSM) and a Certified Sexual Counselor by the American Association of Sexuality Educators, Counselors and Therapists (AASECT). He served as a member of the Standards Committee for the International Society for Sexual Medicine during their 2016 International Consensus Meeting.

Dr. Krychman is an internationally recognized expert and author of numerous books addressing sexual health conditions, therapies, and treatments. He also is a primary and contributing author of many scientific clinical papers, manuscripts and presentations. Frequently asked to share his knowledge on sexual health issues, Dr. Krychman has been quoted in The Wall Street Journal, The New York Times and other media and press.

He has been a visiting professor at Oxford University in the United Kingdom and has served in a consulting or advisory board role for many women’s health companies including SHIONOGI, Boehringer Ingelheim, Pfizer Women’s Healthcare, and Viveve Medical, Inc.

W. Grant Stevens, M.D.

Dr. Stevens is board certified by the American Board of Plastic Surgery and is a clinical professor of plastic surgery at the University of Southern California, chairman of the USC-Marina Aesthetic Surgery Fellowship and director of the USC Division of Aesthetic Surgery. He is a fellow of the American College of Surgeons and the International College of Surgeons. He was appointed by the governor to the Medical Board of California medical quality review board, and is currently co-national secretary and third vice president of the International Society of Aesthetic Plastic Surgery. Dr. Stevens also serves on the editorial board for the Aesthetic Surgery Journal. He is president elect for the American Society for Aesthetic Plastic Surgery and will become president in April, 2018. He earned his medical degree from Washington University School of Medicine in St. Louis, Missouri, and completed his general surgery training at Harbor-UCLA Medical Center.

Dr. Stevens also received additional training in plastic and reconstructive surgery through a competitive fellowship at Washington University-Barnes Hospital. He is the past chairman of the California Medical Association Advisory Panel on Plastic Surgery and received the Special Congressional Certificate of Recognition and the Distinguished Service Citation from the Medical Board of California.

Dr. Stevens has presented at more than 100 meetings and delivered over 300 invited talks both nationally and internationally. Additionally, he has authored more than 70 articles and chapters on aesthetic plastic surgery.